系统性IL-26增加与严重的COVID-19和并发性阻塞性肺病相关
Eduardo I Cardenas1,2, Josefina Robertson3,4, Salvia Misaghian5
1Division of Lung and Airway Research, Institute of Environmental Medicine, and the Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Frontiers in immunology
|October 21, 2024
概括
系统性干白素-26 (IL-26) 在严重的COVID-19中升高,特别是在男性和患有阻塞性肺病的人群中. 这表明IL-26在疾病严重程度上起作用,并可能作为生物标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 肺部病理学 肺部病理学
背景情况:
- 介素-26 (IL-26) 对于肺部防御至关重要,并表现出抗菌和抗病毒性质.
- 以前的研究将急性COVID-19中增加的IL-26与高炎症联系在一起,但其与疾病严重程度,性别,并发症,病毒载荷和先天免疫力的关系仍然不清楚.
研究的目的:
- 调查系统IL-26水平与急性COVID-19中的临床参数之间的关联.
- 探索IL-26与疾病严重程度,性别,并发症,病毒载荷和先天免疫反应的相关性.
主要方法:
- 从使用ELISA的178名COVID-19患者和30名对照者的血中量化IL-26.
- 使用免疫测试和度测量测量了SARS-CoV-2蛋白质,干扰素 (IFN) 和细胞外DNA.
主要成果:
- 在严重/危急的COVID-19患者中观察到IL-26血度升高,特别是男性和患有阻塞性肺病的人.
- IL-26水平与住院时间,病毒载荷标记,抗病毒免疫力和细胞外DNA正相关.
结论:
- 系统性IL-26与严重的COVID-19病原体有关,特别是在男性和患有阻塞性肺病的患者中.
- 研究结果支持IL-26在COVID-19中的致病性和抗病毒相关性,强调其作为生物标志物的潜力.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:29Pneumonia II: Pathophysiology
225
The pathophysiology of pneumonia involves the following steps:
225
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:17Other Pulmonary Disorders
804
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
804
01:30Acute Respiratory Failure-III
161
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
161